Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 7 Esophageal Squamous Cell Carcinoma 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Colorectal Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3 Advanced Solid Tumor 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Nasopharyngeal Neoplasms 2 Head and Neck Neoplasms 2 Breast Neoplasms 2 Advanced Breast Cancer 2 Urinary Bladder Neoplasms 1 Turcot syndrome 1 Solid Tumor 1 Skin Neoplasms 1 Sarcoma 1 Recurrence 1 Papillomavirus Infections 1 Pancreatic Cancer Metastatic 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Mouth Neoplasms 1 Meningeal Carcinomatosis 1 Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

Bevacizumab 35 Paclitaxel 31 Carboplatin 24 pembrolizumab 23 Specimen Handling 21 Magnetic Resonance Spectroscopy 19 Gemcitabine 18 olaparib 16 liposomal doxorubicin 16 Cyclophosphamide 15 fludarabine 12 Topotecan 12 Biopsy 12 niraparib 11 Cisplatin 10 Taxes 8 Nivolumab 8 Immunoglobulin G 8 Fulvestrant 8 Disulfides 8 Doxorubicin 7 aldesleukin 6 Surveys and Questionnaires 6 palbociclib 5 Oxaliplatin 5 Fluorouracil 5 trastuzumab deruxtecan 4 oregovomab 4 mirvetuximab soravtansine 4 X-Rays 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × toripalimab × 90 days × Clear all

NCT04918186 2026-05-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡